The present invention relates to pharmaceutical compositions containing dimethyl fumarate (DMF), More specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg ± 5% or 400 mg ± 5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.